Compare · ABEO vs TSHA
ABEO vs TSHA
Side-by-side comparison of Abeona Therapeutics Inc. (ABEO) and Taysha Gene Therapies Inc. (TSHA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ABEO focuses on Biotechnology: Pharmaceutical Preparations, while TSHA focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- TSHA is the larger of the two at $2.02B, about 5.7x ABEO ($355.1M).
- TSHA has been more active in the news (8 items in the past 4 weeks vs 6 for ABEO).
- TSHA has more recent analyst coverage (17 ratings vs 7 for ABEO).
- Company
- Abeona Therapeutics Inc.
- Taysha Gene Therapies Inc.
- Price
- -
- -
- Market cap
- $355.1M
- $2.02B
- 1M return
- -
- +11.53%
- 1Y return
- -
- +109.83%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 6
- 8
- Recent ratings
- 7
- 17
Abeona Therapeutics Inc.
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in New York, New York.
Taysha Gene Therapies Inc.
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; and TSHA-102 for the treatment of Rett syndrome. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments; and collaboration with Yale University to advance mini-gene payloads for an AAV gene therapy for the treatment of neurodevelopmental disorders. The company was incorporated in 2019 and is based in Dallas, Texas.
Latest ABEO
- SEC Form 10-Q filed by Abeona Therapeutics Inc.
- Abeona Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update
- Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
- CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®
- Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Chief Financial Officer Vazzano Joseph Walter sold $9,651 worth of shares (1,478 units at $6.53), decreasing direct ownership by 0.30% to 492,079 units (SEC Form 4) to satisfy withholding tax
- Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®
- SEC Form 424B3 filed by Abeona Therapeutics Inc.
- Chief Financial Officer Vazzano Joseph Walter sold $173,257 worth of shares (24,880 units at $6.96), decreasing direct ownership by 5% to 493,557 units (SEC Form 4) (withholding tax)
Latest TSHA
- Amendment: SEC Form SCHEDULE 13G/A filed by Taysha Gene Therapies Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Taysha Gene Therapies Inc.
- SEC Form 10-Q filed by Taysha Gene Therapies Inc.
- Taysha Gene Therapies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11
- Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
- President and Head of R&D Nagendran Sukumar sold $1,248,000 worth of shares (200,000 units at $6.24) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 936,410 units (SEC Form 4)
- SEC Form 144 filed by Taysha Gene Therapies Inc.